Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharma (PCRX) Misses Q2 EPS by 8c
August 2, 2017 7:33 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of ($0.11), $0.08 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $70.9 million versus the consensus estimate of $73.6 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More